See more : Manchester United plc (MANU) Income Statement Analysis – Financial Results
Complete financial analysis of Global Technologies, Ltd. (GTLL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Global Technologies, Ltd., a leading company in the Conglomerates industry within the Industrials sector.
You may be interested
- Stream Media Corporation (4772.T) Income Statement Analysis – Financial Results
- Spring Valley Acquisition Corp. II (SVIIR) Income Statement Analysis – Financial Results
- Sakata Seed Corporation (1377.T) Income Statement Analysis – Financial Results
- Safehold Inc. (SAFE) Income Statement Analysis – Financial Results
- SG FINSERVE LIMITED (SGFIN.BO) Income Statement Analysis – Financial Results
Global Technologies, Ltd. (GTLL)
About Global Technologies, Ltd.
Global Technologies, Ltd., through its subsidiaries, engages in the online sale of CBD and hemp related products in the United States. The company operates a portal that provides access to live shopping, e-commerce, and product placement in brick and mortar retail outlets. It also offers sales and distribution, and third-party logistics services, as well as consulting services. Global Technologies, Ltd. was incorporated in 1999 and is based in Saint Petersburg, Florida.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.06M | 17.00K | 124.51K | 15.00K | 548.35K | 0.00 | 0.00 | 290.30K | 7.40M | 1.60M | 19.10M | 11.10M | 2.70M | 100.00K |
| Cost of Revenue | 576.63K | 5.19K | 13.00K | 0.00 | 70.85K | 0.00 | 0.00 | 231.84K | 3.85M | 1.60M | 14.50M | 23.10M | 4.10M | 800.00K |
| Gross Profit | 481.06K | 11.81K | 111.51K | 15.00K | 477.50K | 0.00 | 0.00 | 58.46K | 3.55M | 0.00 | 4.60M | -12.00M | -1.40M | -700.00K |
| Gross Profit Ratio | 45.48% | 69.46% | 89.56% | 100.00% | 87.08% | 0.00% | 0.00% | 20.14% | 47.98% | 0.00% | 24.08% | -108.11% | -51.85% | -700.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.10M | 7.80M | 7.80M | 0.00 |
| General & Administrative | 676.89K | 535.02K | 605.60K | 361.61K | 706.71K | 207.64K | 351.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.93K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 676.89K | 535.02K | 605.60K | 361.61K | 706.71K | 207.64K | 358.83K | 19.25M | 21.21M | 6.70M | 11.40M | 11.70M | 17.00M | 4.80M |
| Other Expenses | 16.15K | 540.21K | 5.19K | 5.20K | 3.03K | -309.25K | 0.00 | 1.15M | 2.08M | 400.00K | 0.00 | 1.30M | 1.80M | 800.00K |
| Operating Expenses | 676.89K | 540.21K | 610.79K | 366.80K | 709.74K | 207.64K | 358.83K | 20.40M | 23.29M | 7.10M | 13.80M | 21.30M | 17.50M | 5.60M |
| Cost & Expenses | 1.27M | 540.21K | 623.79K | 366.80K | 780.59K | 207.64K | 358.83K | 20.63M | 27.13M | 8.70M | 28.30M | 44.40M | 21.60M | 6.40M |
| Interest Income | 0.00 | 88.03K | 7.52K | 12.20K | 1.86K | 253.19K | 18.70K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 898.48K | 88.03K | 493.85K | 1.18M | 1.64M | 253.19K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 900.00K |
| Depreciation & Amortization | 16.15K | 5.19K | 5.19K | 5.20K | 3.03K | 207.64K | 358.83K | -2.80M | -2.08M | -400.00K | -1.30M | -1.80M | -500.00K | -800.00K |
| EBITDA | 1.73M | -940.82K | -801.65K | -3.27M | 1.09M | -516.89K | -159.35K | -28.76M | -17.66M | -7.70M | -9.80M | -31.50M | -18.10M | -5.80M |
| EBITDA Ratio | 163.25% | -3,047.18% | -565.41% | -20,706.89% | -200.67% | 0.00% | 0.00% | -1,766.23% | -43.74% | -156.25% | -51.31% | -125.23% | -666.67% | -5,800.00% |
| Operating Income | -211.98K | -523.21K | -499.29K | -351.80K | -232.24K | -207.64K | -358.83K | -37.33M | -19.74M | -7.10M | -8.50M | -9.20M | -33.30M | -6.30M |
| Operating Income Ratio | -20.04% | -3,077.72% | -401.02% | -2,345.36% | -42.35% | 0.00% | 0.00% | -12,860.49% | -266.83% | -443.75% | -44.50% | -82.88% | -1,233.33% | -6,300.00% |
| Total Other Income/Expenses | 1.02M | -510.83K | -779.03K | -3.88M | -318.71K | -562.44K | -159.35K | -15.50M | -14.42M | 2.88M | 1.24M | -17.72M | -666.90K | 968.72K |
| Income Before Tax | 812.08K | -1.03M | -1.28M | -4.23M | -550.94K | -770.09K | -518.18K | -48.60M | -34.16M | -11.30M | -6.60M | -26.80M | -33.70M | -6.00M |
| Income Before Tax Ratio | 76.78% | -6,082.59% | -1,026.71% | -28,191.07% | -100.47% | 0.00% | 0.00% | -16,740.98% | -461.79% | -706.25% | -34.55% | -241.44% | -1,248.15% | -6,000.00% |
| Income Tax Expense | 0.00 | 88.03K | 779.03K | 1.18M | 1.64M | 309.25K | -358.83K | -11.26M | 20.62M | -3.90M | 700.00K | 21.30M | 1.40M | 1.20M |
| Net Income | 812.08K | -1.03M | -1.28M | -4.23M | -550.00K | -1.08M | -518.18K | -34.67M | -36.19M | -2.40M | -7.30M | -51.00M | -19.30M | -5.30M |
| Net Income Ratio | 76.78% | -6,058.82% | -1,028.06% | -28,200.00% | -100.30% | 0.00% | 0.00% | -11,941.66% | -489.28% | -150.00% | -38.22% | -459.46% | -714.81% | -5,300.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00 | -3.68 | -0.29 | -0.81 | -5.93 | -3.20 | -1.85 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00 | -3.68 | -0.29 | -0.81 | -5.93 | -3.20 | -1.85 |
| Weighted Avg Shares Out | 14.68B | 14.43B | 12.34B | 14.98B | 12.19B | 12.19B | 12.11B | 11.54M | 9.84M | 8.28M | 9.01M | 8.60M | 6.03M | 2.86M |
| Weighted Avg Shares Out (Dil) | 14.68B | 14.43B | 12.34B | 14.98B | 12.19B | 12.19B | 12.11B | 11.54M | 9.84M | 8.28M | 9.01M | 8.60M | 6.03M | 2.86M |
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zeta Global Holdings
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Zeta To Contact Him Directly To Discuss Their Options
Data Center World Global Conference Announces NVIDIA VP Marc Hamilton to Deliver Keynote Address
SAN FRANCISCO--(BUSINESS WIRE)--Data Center World, the leading global conference for data center IT infrastructure, mission-critical facilities management, new power designs and solutions, emerging construction practices, and the innovative tools and technologies needed to become an AI factory, today announced that...
BofA Global Research Expects 2025 to be a Year of Further Equity Market Strength Amid Macro Uncertainty
BofA Economists and Strategists Forecast the US Economy to Continue to Outperform and the S&P 500 to Reach 6666 by Year-end NEW YORK , Dec. 3, 2024 /PRNewswire/ -- While we await key details on policy changes in the US,...
DiDi Global: A Solid Quarter, Change In Accounting Standard Signals Potential Hong-Kong Listing
DiDi Global's Q3 2024 results show slower volume growth in China but improved profitability, with record-high operating profits and increased monetization rates. The change from U.S. GAAP to IFRS suggests a potential Hong Kong listing. DiDi's balance sheet remains robust,...
Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
Global Uranium Engages Big Rock Exploration to Advance Wyoming Uranium Projects
Global Uranium is Leveraging Big Rock Exploration's Expertise to Accelerate Drill Readiness and Target Refinement in Wyoming Global Uranium is Leveraging Big Rock Exploration's Expertise to Accelerate Drill Readiness and Target Refinement in Wyoming
Data Quality Driving Regulatory Reporting Decision-Making, according to S&P Global Market Intelligence Cappitech Survey
Extensive use of manual practices a key barrier to high quality data and efficient operational processes NEW YORK , Dec. 3, 2024 /PRNewswire/ -- S&P Global Market Intelligence today released the findings of its annual Global Regulatory Reporting Survey, highlighting that...
Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
Global licensing agreement grants Elevar Therapeutics worldwide rights to develop and commercialize lirafugratinib (RLY-4008)
High Tide: Cabana Club Goes Global
High Tide announced the global expansion of Cabana Club with CBD, accessory, and snack sales into the US, EU, and UK markets. The immediate earnings potential is limited, but the strategic potential of the brand's market expansion is significant. HITI...
WeRide Named to Fortune Future 50 List, Recognizing Global Leadership in Autonomous Driving Tech
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- WeRide Inc. (“WeRide” or the “Company”) (Nasdaq: WRD), a global autonomous driving leader, today was named to the 2024 Fortune Future 50 List, which ranks the world's top public and private companies...
Source: https://incomestatements.info
Category: Stock Reports